(RTTNews) - SERB Pharmaceuticals (SERB), and Y-mAbs Therapeutics, Inc. (YMAB) have entered into a definitive merger agreement under which SERB will acquire Y-mAbs, including its lead commercial oncology asset, DANYELZA, in an all-cash transaction, representing an equity value for Y-mAbs of approximately $412 million. SERB will commence an all-cash tender offer to purchase all outstanding shares of Y-mAbs common stock. Holders of Y-mAbs common stock would receive $8.60 per share in cash.
Y-mAbs stockholders holding approximately 16% of Y-mAbs outstanding shares have entered into a tender and support agreement with SERB, pursuant to which such stockholders have agreed to tender all of their shares of Y-mAbs common stock in the tender offer.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
